medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number 3

<< Back Next >>

Acta Med 2021; 19 (3)

Paraneoplastic syndromes associated with lung cancer

Núñez HJC, Tamariz CAF, Mellado OR, Tostado CR, Díaz GEJ, Rodríguez WFL

Language: Spanish
References: 27
Page: 346-353
PDF size: 176.75 Kb.


ABSTRACT

Paraneoplastic syndromes are defined as a set of signs and symptoms that appear in distant locations from the underlying malignancy or its metastases in the oncological patient, secondary to the secretion of substances by the tumor or by the development of antibodies directed against tumor antigens, which develop a cross-reaction with other tissues. Among the cancers that most frequently develop these syndromes is lung cancer. The presence of some of these paraneoplastic syndromes can guide us to know the histological line of lung cancer. Similarly, many of these syndromes tend to appear before diagnosis, and may even indicate the prognosis of this cancer.


REFERENCES

  1. Midthun DE. UpToDate. Uptodate.com. 2020. Available in: https://www.uptodate.com/contents/overview-of-the-risk-factors-pathology-and-clinical-manifestations-of-lung-cancer?search=paraneoplastic%20syndromes%20lung%20cancer&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

  2. Cancer Today. Gco.iarc.fr. 2018. Available in: https://gco.iarc.fr/today/online-analysis-table?v=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1

  3. Tan W. Non-small cell lung cancer (NSCLC): practice essentials, background, pathophysiology [Internet]. Emedicine.medscape.com. 2019 [cited 25 March 2020]. Available in: https://emedicine.medscape.com/article/279960-overview

  4. Stella GM, Kolling S, Benvenuti S, Bortolotto C. Lung-seeking metastases. Cancers (Basel). 2019; 11 (7): 1010. doi: 10.3390/cancers11071010.

  5. Thomas K, Gould M. UpToDate. Uptodate.com. 2020. Available in: https://www.uptodate.com/contents/overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer?search=lung%20cancer&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2

  6. Anwar A, Jafri F, Ashraf S, Jafri MAS, Fanucchi M. Paraneoplastic syndromes in lung cancer and their management. Ann Transl Med. 2019; 7 (15): 359. doi: 10.21037/atm.2019.04.86.

  7. Nikoomanesh K, Choi J, Arabian S. Paraneoplastic syndrome as the presentation of limited stage small cell carcinoma. BMC Pulm Med. 2018; 18 (1): 169. doi: 10.1186/s12890-018-0729-y.

  8. Bentea G, Sculier C, Grigoriu B, Meert AP, Durieux V, Berghmans T et al. Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. Lung Cancer. 2017; 106: 83-92. doi: 10.1016/j.lungcan.2017.01.017.

  9. Sculier C, Bentea G, Ruelle L, Grigoriu B, Coureau M, Gorham J et al. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions. Lung Cancer. 2017; 111: 164-175. doi: 10.1016/j.lungcan.2017.07.026.

  10. Shen K, Xu Y, Guan H, Zhong W, Chen M, Zhao J et al. Paraneoplastic limbic encephalitis associated with lung cancer. Sci Rep. 2018; 8 (1): 6792. doi: 10.1038/s41598-018-25294-y.

  11. Maddison P, Gozzard P, Sadalage G, Ambrose PA, Chapman CJ, Murray A et al. Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome. J Neuroimmunol. 2020; 340: 577149. doi: 10.1016/j.jneuroim.2020.577149.

  12. Cai G, Sun X, Yu J, Meng X, Li J. Non-small cell lung cancer associated with late-onset Lambert-Eaton myasthenic syndrome and paraneoplastic cerebellar degeneration. Neurol Sci. 2020; 41 (5): 1277-1279. doi: 10.1007/s10072-019-04139-0.

  13. Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014; 5 (3): 197-223. doi: 10.5306/wjco.v5.i3.197.

  14. Ruelle L, Bentea G, Sideris S, El Koulali M, Holbrechts S, Lafitte JJ et al. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. Lung Cancer. 2017; 111: 150-163. doi: 10.1016/j.lungcan.2017.07.025.

  15. Efthymiou C, Spyratos D, Kontakiotis T. Endocrine paraneoplastic syndromes in lung cancer. Hormones (Athens). 2018; 17 (3): 351-358. doi: 10.1007/s42000-018-0046-0.

  16. Kosuda A, Shirahata T, Kudo N, Uehara Y, Miyawaki M, Hagiwara A et al. Long-term survival of a patient with small cell lung cancer secreting ADH and ACTH simultaneously, following the prolonged use of amrubicin. Intern Med. 2020; 59 (1): 107-112. doi: 10.2169/internalmedicine.2838-19.

  17. Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Paraneoplastic endocrine syndromes. Endocr Relat Cancer. 2017; 24 (6): R173-R190. doi: 10.1530/ERC-17-0036.

  18. Agarwal KA, Soe MH. Beyond the dual paraneoplastic syndromes of small-cell lung cancer with ADH and ACTH secretion: a case report with literature review and future implications. Case Rep Oncol Med. 2018; 2018: 4038397. doi: 10.1155/2018/4038397.

  19. Suarez A, Faber B, Stanton A. A smoker with joint pain. BMJ. 2017; 358: j3149. doi: 10.1136/bmj.j3149.

  20. Zhang T, Wu Q, Qin S, Wang Z, Li Y, Wang R et al. Lung cancer with dermatomyositis as the initial diagnosis: a case report. Mol Clin Oncol. 2019; 11 (1): 59-62. doi: 10.3892/mco.2019.1851.

  21. Gameiro R, Gomes R, Jorge V, Picado B, Goncalves FM, Araújo JL. A paraneoplastic syndrome to remember: a case of disseminated intravascular coagulation in lung cancer. Eur J Case Rep Intern Med. 2019; 6 (6): 001134. doi: 10.12890/2019_001134.

  22. Karthik R, Mohan N, Ravi Kumar PT, Fenn SM. Cutaneous manifestations of internal malignancy. Int J Contemp Med Res. 2017; 4 (4): 935-939. Available in: https://www.ijcmr.com/uploads/7/7/4/6/77464738/ijcmr_1410_may_20.pdf

  23. Owen CE. Cutaneous manifestations of lung cancer. Semin Oncol. 2016; 43 (3): 366-369. doi: 10.1053/j.seminoncol.2016.02.025.

  24. Arandes-Marcocci J, Iglesias-Sancho M, Setó-Torrent N, Fernández-Figueras MT. Erythroderma as first manifestation of squamous cell lung cancer: rare case report. An Bras Dermatol. 2020; 95 (1): 67-70. doi: 10.1016/j.abd.2019.05.004.

  25. Holbrechts S, Gorham J, Sideris S, Meert AP, Durieux V, Berghmans T et al. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes. Lung Cancer. 2017; 106: 93-101. doi: 10.1016/j.lungcan.2017.01.016.

  26. Durieux V, Coureau M, Meert AP, Berghmans T, Sculier JP. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. Lung Cancer. 2017; 106: 102-109. doi: 10.1016/j.lungcan.2017.01.015.

  27. Aytekin A, Ozet A, Bilgetekin I, Ogut B, Ciltas A, Benekli M. A case of membranous glomerulopathy associated with lung cancer and review of the literature. Mol Clin Oncol. 2017; 7 (2): 241-243. doi: 10.3892/mco.2017.1295.




2020     |     www.medigraphic.com